Noradrenergic and specific serotonergic antidepressants (NaSSAs) are a class of psychotropic medications primarily used in the treatment of major depressive disorder. These medications work by affecting the levels of neurotransmitters, specifically norepinephrine and serotonin, in the brain.
NaSSAs are considered to be dual-action antidepressants, as they simultaneously target both the noradrenergic and serotonergic systems. They modulate the activity of norepinephrine by blocking its reuptake, thus increasing its availability in the synapse. Additionally, they block certain serotonin receptors, resulting in increased serotonergic transmission. This dual mechanism of action distinguishes NaSSAs from other antidepressant classes.
By influencing the levels of norepinephrine and serotonin, NaSSAs aim to restore the imbalance of these neurotransmitters in individuals with depression. This restoration is believed to enhance mood, reduce symptoms of depression, and improve overall mental well-being.
Common examples of NaSSAs include mirtazapine and mianserin. These medications are prescribed after considering various factors such as the severity of depression, previous medication response, and potential side effects. NaSSAs are generally safe and well-tolerated, although they may still carry certain side effects including drowsiness, increased appetite, and weight gain.
While NaSSAs are primarily used for depression, they may also be prescribed for other conditions such as anxiety disorders and insomnia. However, it is important to note that NaSSAs should only be used as directed by a healthcare professional, as individual responses to these medications can vary.
